全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Sasagu Kurozumi , Hiroshi Matsumoto , Yuji Hayashi ...
来源:[J].BMC Cancer(IF 3.333), 2017, Vol.17 (1)Springer
摘要:The Ki67 labeling index (LI) is regarded as a significant prognostic marker in ER-positive/HER2-negative breast cancer patients. The expression of PgR has recently been identified as another prognostic marker. In the present study, we investigated the prognostic utilities and mos...
作者:Wei Wu , Heran Deng , Nanyan Rao ...
来源:[J].Trials(IF 2.206), 2017, Vol.18 (1)Springer
摘要:The response to neoadjuvant chemotherapy (NAC) varies by estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) statuses, with responses being lower in ER-positive, HER2-negative tumors as compared with ER-negative, HER2-positive or triple-negative tumors. Neo...
作者:Yuji Yamashita , Shin Nishiumi , Seishi Kono ...
来源:[J].BMC Cancer(IF 3.333), 2017, Vol.17 (1)Springer
摘要:Triple-negative breast cancer (TN) is more aggressive than other subtypes of breast cancer and has a lower survival rate. Furthermore, detailed biological information about the disease is lacking. This study investigated characteristics of metabolic pathways in TN.
作者:Denise A. Yardley , Dianna Shipley , John Zubkus ...
来源:[J].Clinical Breast Cancer(IF 2.422), 2018Elsevier
摘要:Abstract(#br)Background(#br)Eribulin mesylate is a non-taxane microtubule inhibitor effective in the treatment of metastatic breast cancer refractory to anthracyclines and taxanes. In preclinical studies, additional mechanisms of eribulin included reversal of epithelial mesenchym...
作者:Joyce O’Shaughnessy , Angela DeMichele , Cynthia X. Ma ...
来源:[J].Breast Cancer Research and Treatment(IF 4.469), 2018, Vol.170 (3), pp.547-557Springer
摘要:... This randomized phase 2 trial evaluated the efficacy and safety of the addition of ruxolitinib, a JAK1/JAK2 inhibitor, to capecitabine in patients with HER2-negative advanced breast cancer and high systemic inflammation (modified Glasgow Prognostic Score [mGPS] ≥ 1).(#br) ...
作者:Denise A. Yardley , Nancy W. Peacock , Mythili Shastry ...
来源:[J].Breast Cancer Research and Treatment(IF 4.469), 2015, Vol.154 (2), pp.299-308Springer
摘要:Abstract(#br)Ixabepilone and the taxanes have similar activity in the first-line treatment of metastatic breast cancer, and ixabepilone is sometimes effective in taxane-refractory patients. We conducted a phase 2 trial to evaluate ixabepilone in combination with cyclophosphamid...
作者:Takashi Ishikawa , Kouhei Akazawa , Yoshie Hasegawa ...
来源:[J].Journal of Surgical Research(IF 2.018), 2017, Vol.220, pp.46-51Elsevier
摘要:Abstract(#br)Background(#br)A randomized phase 2 trial in women with HER2-negative breast cancer has shown that adding zoledronic acid (ZOL) to neoadjuvant chemotherapy (CT) has potential anticancer benefits in postmenopausal and triple-negative (TN) breast cancer patients. We re...
作者:Denise A. Yardley , Natalie Dickson , David Drosick ...
来源:[J].Clinical Breast Cancer(IF 2.422), 2016, Vol.16 (3), pp.180-187Elsevier
摘要:Abstract(#br)Background(#br)The purposes of the present phase I/II trial were (1) to define tolerable doses of ixabepilone and sorafenib when used in combination and (2) to evaluate the efficacy and toxicity of this combination in the treatment of patients with human epidermal growth factor receptor-negative metastatic breast cancer...
作者:Akiko Ogiya , Kieko Yamazaki , Rie Horii ...
来源:[J].Breast Cancer(IF 1.33), 2017, Vol.24 (3), pp.473-482Springer
摘要:Few studies have been performed on post-relapse survival in patients with the early and late distant recurrence in estrogen receptor (ER)-positive, HER2-negative breast cancer.
作者:Anna Miquel-Cases , Lotte M. G. Steuten , Lisanne S. Rigter ...
来源:[J].BMC Cancer(IF 3.333), 2016, Vol.16 (1)Springer
摘要:Abstract(#br) Background(#br)Response-guided neoadjuvant chemotherapy (RG-NACT) with magnetic resonance imaging (MRI) is effective in treating oestrogen receptor positive/human epidermal growth factor receptor-2 negative (ER-positive/HER2-negative) breast cancer. We estimated ...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×